Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026)
Precigen's (PGEN) quarterly Total Non-Current Liabilities came in at $118.3 million in Q1 2026, up 290.24% year-on-year from $30.3 million in Q1 2025, and down 12.03% on a QoQ basis from $134.5 million in Q4 2025.
Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Total Non-Current Liabilities data on file, last reported at $118.3 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 290.24% year-over-year to $118.3 million in Q1 2026; TTM through Mar 2026 was $118.3 million, a 290.24% increase from a year earlier, with the FY2025 full-year figure at $134.5 million, up 71.21% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $118.3 million, down from $134.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for PGEN reached as high as $261.7 million in Q1 2022 and fell as low as $29.2 million in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $101.8 million across 5 years, with a median of $98.4 million in 2024.
- Across the five-year window, Total Non-Current Liabilities climbed 12.75% in 2022 and soared 290.24% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $261.7 million in 2022, then slumped by 87.56% to $32.5 million in 2023, then soared by 141.31% to $78.5 million in 2024, then surged by 71.21% to $134.5 million in 2025, then fell by 12.03% to $118.3 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $118.3 million in Q1 2026, $134.5 million in Q4 2025, and $129.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | 118.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.29 Mn |
| Dec 31, 2025 | 134.46 Mn |
| Sep 30, 2025 | 129.40 Mn |
| Jun 30, 2025 | 29.23 Mn |
| Mar 31, 2025 | 30.31 Mn |
| Dec 31, 2024 | 78.54 Mn |
| Dec 31, 2023 | 32.55 Mn |
| Mar 31, 2022 | 261.68 Mn |
| Dec 31, 2021 | 252.46 Mn |
| Sep 30, 2021 | 245.60 Mn |
| Jun 30, 2021 | 243.33 Mn |
| Mar 31, 2021 | 232.09 Mn |
| Dec 31, 2020 | 247.31 Mn |
| Sep 30, 2020 | 277.53 Mn |
| Jun 30, 2020 | 312.07 Mn |
| Dec 31, 2019 | 88,000.00 |
| Sep 30, 2019 | 376.26 Mn |
| Jun 30, 2019 | 375.74 Mn |
| Mar 31, 2019 | 374.38 Mn |
| Dec 31, 2018 | 334.32 Mn |